NEW YORK (GenomeWeb) – Illumina said today that an expanded version of its VeriSeq NIPT software to analyze fetal aneuploidies has met the requirements of the EU's in vitro diagnostic directive and it will apply the CE mark to the software.

The VeriSeq NIPT test is a noninvasive prenatal test that analyzes fetal aneuploidy for chromosomes 21, 18, 13, as well as the sex chromosomes.

The updated software includes a new method for processing samples and an increase in the number of samples it can batch from 16 to 48.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.